AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22863206
Drug: Qigong training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qigong training (level 1 Chaoyi Fanhuan Qigong, CFQ), given over three half‐days, followed by weekly review/practice sessions for eight weeks, with home practice for 45 to 60 minutes per day.
Trial: 21058479
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group of Four Points of Throat acupuncture and routine medication (group 1)
Trial: 21058479
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication only (group 2)
Trial: 15861018
Drug: omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole + amoxicillin with metronidazole
Trial: 15861018
Drug: omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole + amoxicillin with clarithromycin
Trial: 15861018
Drug: omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole + amoxicillin with metronidazole (metronidazole-susceptible bacteria)
Trial: 15861018
Drug: omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole + amoxicillin with metronidazole (metronidazole-resistant bacteria)
Trial: 15861018
Drug: omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole + amoxicillin with clarithromycin (clarithromycin-sensitive strains)
Trial: 15861018
Drug: omeprazole +
RxNorm normalized name: Omeprazole + SyrSpend SF Alka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole + amoxicillin with clarithromycin (clarithromycin-resistant strains)
Trial: 11967720
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Ang II infusion (A)
Trial: 11967720
Drug: Valsartan +
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan + Ang II infusion (VA)
Trial: 9464723
Drug: Intravaginal PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal PGE2 gel (2 mg)
Trial: 9464723
Drug: Intracervical PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical PGE2 gel (0.5 mg)
Trial: 7796228
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin administration for prophylaxis
Trial: 7796228
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin administration for treatment
Trial: 7008655
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 1 or 2 mg
Trial: 31792878
Drug: Morphine drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine drops with ethanol (red morphine drops, RMD)
Trial: 31792878
Drug: Morphine drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine drops without ethanol
Trial: 26106113
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue-type plasminogen activator (IV r‐tPA)
Trial: 21129341
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose monitoring system (CGMS) with low glucose alarm set at 80 mg/dl for 3 days
Trial: 15883637
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg daily for 2 years, then 10 mg for 1-2.5 years)
Trial: 15603033
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg misoprostol vaginal gel
Trial: 15603033
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of prostaglandin E2 gel
Trial: 9481721
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous intradialysis rHuEpo therapy
Trial: 9481721
Drug: Intravenous postdialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous postdialysis rHuEpo therapy (control)
Trial: 791537
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (one or more aortocoronary saphenous vein bypass grafts)
Trial: 791537
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (conventional medical treatment)
Trial: 31407549
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg TXA administered intravenously before 5-10 minutes of operation (Group A)
Trial: 31407549
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg TXA administered intravenously before 5-10 minutes of operation (Group B)
Trial: 28697050
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin 7-8 g/dL)
Trial: 28697050
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin 10-11 g/dL)
Trial: 26673788
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with bevacizumab (BEV) in combination with cytoreductive surgery (CRS) and oxaliplatin-based intraperitoneal chemoperfusion (IPC)
Trial: 26673788
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with bevacizumab (BEV)
Trial: 23531438
Drug: 2.5mg oral
RxNorm normalized name: NALOXEGOL 12.5MG ORAL TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg oral tibolone (n=11)
Trial: 23531438
Drug: 1.25mg oral
RxNorm normalized name: Glyburide 1.25mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25mg oral tibolone (n=13)
Trial: 17719314
Drug: Atorvastatin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (both dosages)
Trial: 8250306
Drug: Sufentanil 10
RxNorm normalized name: SUFentanil 100 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 10 micrograms plus morphine 250 micrograms
Trial: 3114189
Drug: Pion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pion therapy
Trial: 10396321
Drug: 5'-DFUR (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR (800 mg daily for 3 weeks)
Trial: 17167280
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for primary and secondary prevention of CHD
Trial: 15519288
Drug: OTC lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OTC lovastatin 20 mg
Trial: 9663360
Drug: Domperidone 20
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 20 mg QID for 4 weeks
Trial: 3134859
Drug: MQF-OK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MQF-OK therapy with UFT (group B)
Trial: 3134859
Drug: MQF-OK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MQF-OK therapy with FT (group A)
Trial: 15531318
Drug: Radiotherapy (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (20 Gy delivered in 5 daily fractions of 4 Gy each; 6 MV)
Trial: 8072721
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists in chronic haemodialysis patients
Trial: 8072721
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment in normotensive patients with microalbuminuric diabetes or non-diabetic uraemic nephropathy
Trial: 8072721
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors in diabetic nephropathy and non-diabetic uraemic nephropathy
Trial: 25135262
Drug: Triamcinolone 0.1%
RxNorm normalized name: TRIAMCINOLONE 0.1% CREAM/SILICONE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone 0.1% cream
Trial: 18305467
Drug: Cyclosporine with
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine with adjusted dosage to maintain trough levels of 60-80 ng/ml in Group A
Trial: 18305467
Drug: Cyclosporine with
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine with fixed dosage of 2.5 mg/kg/day in Group B
Trial: 16597078
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (positive control)
Trial: 12678512
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg I.M. with 20 mg chlorpheniramine maleate (CPM)
Trial: 12678512
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (CPM, 20 mg) I.M.
Trial: 8409568
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin 600 mg tds
Trial: 8409568
Drug: Diclofenac dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac dispersible 50 mg tds
Trial: 3954112
Drug: Oral controlled
RxNorm normalized name: Afeditab CR Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral controlled release morphine (30 mg CRM orally)
Trial: 3954112
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (4 mg morphine epidurally)
Trial: 26822799
Drug: Creatine augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine augmentation of escitalopram
Trial: 26822799
Drug: Placebo augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo augmentation of escitalopram
Trial: 25102385
Drug: Activity-based therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-based therapy (ABT) for 24 weeks, 9h/wk including developmental sequencing, resistance training, repetitive, patterned motor activity, and task-specific locomotor training
Trial: 25102385
Drug: Activity-based therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-based therapy (ABT)
Trial: 22485232
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic therapy (control group)
Trial: 15083597
Drug: Statin-fibrate combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin-fibrate combination therapy
Trial: 15083597
Drug: Statin-niacin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin-niacin combination therapy
Trial: 15083597
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of cholesterol ester transfer protein and HDL therapy drugs
Trial: 10780713
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) administered orally, twice a day from 36 weeks' gestation until labor and every 3 hours during labor.
Trial: 3512944
Drug: Physostigmine 0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 0.004 mg/kg
Trial: 3512944
Drug: Physostigmine 0.009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 0.009 mg/kg
Trial: 3512944
Drug: Physostigmine 0.013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 0.013 mg/kg
Trial: 3512944
Drug: Physostigmine (most
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (most effective dose)
Trial: 29071985
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at phenomaxillary ganglia and local acupoints (Yingxiang (LI 20, bilateral) and Yintang (EX-HN 3)) for 20 min, twice per week for 4 weeks.
Trial: 29071985
Drug: Oral loratadine
RxNorm normalized name: loratadine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loratadine tablets for 4 weeks.
Trial: 25344361
Drug: PEB chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEB chemotherapy (cisplatin, etoposide, and bleomycin)
Trial: 25344361
Drug: High-dose sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sequential chemotherapy (HDS)
Trial: 10730021
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (comprehensive drug therapy management program)
Trial: 10730021
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no access to pharmaceutical care)
Trial: 1359809
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (initial dose 170 ng.kg‐1 x min‐1, maintenance 10 ng.kg‐1 x min‐1)
Trial: 8836267
Drug: Piroxicam gel
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam gel 15gm
Trial: 8836267
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic field block with 20 ml of 0.375% bupivacaine
Trial: 1349676
Drug: olsalazine (Dipentum;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olsalazine (Dipentum; 1.0 g daily)
Trial: 1349676
Drug: mesalazine (Asacol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine (Asacol, with Eudragit‐S coating; 1.2 g daily)
Trial: 25688512
Drug: Everolimus in
RxNorm normalized name: Product containing everolimus in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus in combination with octreotide LAR and metformin
Trial: 19205290
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of fluticasone propionate at 200 microg/d for 4 weeks
Trial: 19205290
Drug: Innovator formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovator formulation of fluticasone propionate at 200 microg/d for 4 weeks
Trial: 12396273
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg (14)C‐labelled emedastine difumarate (mass balance study)
Trial: 12396273
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral emedastine difumarate b.i.d. or 4 mg o.d. for 7 consecutive days (single- and multiple-dose pharmacokinetic study)
Trial: 2182581
Drug: TBI/LON (Lonidamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBI/LON (Lonidamine 420 mg/m2 orally daily)
Trial: 121884
Drug: Sodium nivimedone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium nivimedone (200 mg thrice daily)
Trial: 17101711
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg vitamin K1 intramuscularly (control)
Trial: 17101711
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg vitamin K1 intramuscularly
Trial: 17101711
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg vitamin K1 intravenously
Trial: 17101711
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg vitamin K1 intramuscularly
Trial: 15598026
Drug: Timed release
RxNorm normalized name: Mega B 100 Timed Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed release glucosamine sulfate (TimeOsamine) 1,000 mg (2 x 500 mg)
Trial: 15598026
Drug: Powder-filled glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder-filled glucosamine sulfate formulation 1,500 mg (3 x 500 mg)
Trial: 2522729
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 100 mg/day)
Trial: 11499735
Drug: Not specified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not specified (high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy)
Trial: 9269267
Drug: Copper-salicylate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper-salicylate gel (1.5 g) applied twice daily for four weeks
Trial: 9269267
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (1.5 g) applied twice daily for four weeks
Trial: 8387151
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (2 mg E2V and 1 mg CPA)
Trial: 8387151
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (1 mg E2V and 0.5 mg CPA)
Trial: 8387151
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (2 mg E2V and 2 mg CPA)
Trial: 23543732
Drug: Palonosetron (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (75 mcg)
Trial: 20459404
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/day, n=48)
Trial: 20459404
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n=15)
Trial: 16160627
Drug: Tetrahydrobiopterin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrahydrobiopterin (3 mg/kg daily for 6 months)
Trial: 11803237
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (120 mg) in severity stratum 1 (MMSE >23)
Trial: 11803237
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (120 mg) in severity stratum 2 (MMSE <24)
Trial: 11803237
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (120 mg) in patients with very mild to mild cognitive impairment
Trial: 11803237
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (120 mg) in patients with more severe dementia
Trial: 6175494
Drug: Propafenon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenon (3 x 150 mg daily)
Trial: 6175494
Drug: Propranolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (3 x 20 mg daily)
Trial: 26132827
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg body mass)
Trial: 26821116
Drug: BB-12 capsule
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BB-12 capsule (CAP)
Trial: 22763899
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with levobupivacaine 0.375% 20 mL
Trial: 22763899
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block with 20 mL 0.9% saline (Control)
Trial: 15921806
Drug: Carvedilol (stayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (stayed on the same drug)
Trial: 15921806
Drug: Metoprolol (stayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (stayed on the same drug)
Trial: 6467282
Drug: Cefazolin 500
RxNorm normalized name: cefazolin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 500 mg
Trial: 29702283
Drug: Traditional anti-allergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional anti-allergic medications (Control)
Trial: 22991405
Drug: Chronic PDE5I
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic PDE5I (sildenafil® 20 mg tid for 12 weeks followed by 60 mg tid for 12 weeks)
Trial: 15930452
Drug: Olestra-containing diet
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra-containing diet with daily multivitamin (Centrum)
Trial: 8967669
Drug: Accelerated alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accelerated alteplase therapy
Trial: 1725890
Drug: Cromakalim 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim 1 mg
Trial: 1725890
Drug: Cromakalim 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim 2 mg
Trial: 6091484
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g single dose)
Trial: 6091484
Drug: Cefazolin (seven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (seven doses)
Trial: 29633339
Drug: Intraduodenal acetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal acetic acid infusion (50 mL)
Trial: 29633339
Drug: Saline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (50 mL)
Trial: 26791556
Drug: Infancy iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infancy iron supplementation (∼1 mg Fe/(kg · d) as oral iron proteinsuccynilate)
Trial: 20350920
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment (50 to 100 mcg daily)